Author(s):
Mohammad Chand Jamali, Mohammed Abdalhamied M. Abushohada, Anam Tariq, Fahad Saqib Lodhi, Dilbar Urazbaeva, Srikumar Chakravarthi, Joti Devi, Tahlil Nafi, MD. Faisal Ahmed, T. Ramesh, Nikolaos Syrmos, Mustafa Mudhafar
Email(s):
mjamali68@gmail.com
DOI:
10.52711/0974-360X.2026.00549 
Address:
Mohammad Chand Jamali1*, Mohammed Abdalhamied M. Abushohada2, Anam Tariq3, Fahad Saqib Lodhi4, Dilbar Urazbaeva5, Srikumar Chakravarthi6, Joti Devi7, Tahlil Nafi8, MD. Faisal Ahmed9, T. Ramesh10, Nikolaos Syrmos11, Mustafa Mudhafar12
1Liwa University, College of Medical and Health Sciences, Al Ain, Abu Dhabi, UAE.
2Liwa University, College of Medical and Health Sciences, Liwa College, Abu Dhabi, United Arab Emirates.
3Department of Biomedical Sciences, College of Health Sciences, Abu Dhabi University, Abu Dhabi, UAE.
4Department of Public Health and Behavioral Sciences, Dubai Medical College for Girls, Dubai Medical University, Dubai 19099, United Arab Emirates.
5Mamun University, Khive Uzbekistan.
6Deputy Vice Chancellor, Faculty of Medicine, Nursing and Health Sciences, SEGi University, Selangor, Malaysia.
7Hospital Pharmacist, Agha Khan University Hospital, Karachi, Pakistan.
8Department of Biotechnology, Bangladesh Agricultural University, Mymensingh-2202, Banglades
Published In:
Volume - 19,
Issue - 8,
Year - 2026
ABSTRACT:
Human metapneumovirus (HMPV) is a major respiratory disease worldwide due to its impact on vulnerable population families, aging population, and immunosuppressed patients. Although identified in 2001, HMPV is still underreported, and in some regions, its infection has even exceeded such popular issues as COVID-19 and influenza. It is widely witnessed but there is no licensed vaccination or reliably effective antiviral therapy against it. The mode of transmission of HMPV is through respiratory droplets which causes acute respiratory tract infections. The genetic diversity in glycoproteins, or to be specific, the G and F proteins; categorize it into two large genotypes A and B. Previous (old) treatment interventions include nucleoside analogues like ribavirin, fusion inhibitors, interfering RNAs, monoclonal antibodies, and inhibitors, which are sulfated sialyl lipids. Their effectiveness is not being equal, however, and a number of them require more clinical confirmation. The development of vaccines is a work in progress and live attenuated as well as protein-based systems are promising. Better surveillance, proper diagnosis, and preparedness through systems such as the International Health Regulations (IHR) are vital since it is becoming more and more frequent and has the possibility of causing severe co-infections especially post-COVID-19. The paper will offer some future suggestions with regards to the containment and public health response strategies because of synthesizing the existing information about the epidemiology, virology and therapeutic choices of HMPV.
Cite this article:
Mohammad Chand Jamali, Mohammed Abdalhamied M. Abushohada, Anam Tariq, Fahad Saqib Lodhi, Dilbar Urazbaeva, Srikumar Chakravarthi, Joti Devi, Tahlil Nafi, MD. Faisal Ahmed, T. Ramesh, Nikolaos Syrmos, Mustafa Mudhafar. Respiratory Infections by Human Metapneumovirus Epidemiological Evidence and Treatment Prospects. Research Journal of Pharmacy and Technology. 2026;19(8):3905-2. doi: 10.52711/0974-360X.2026.00549
Cite(Electronic):
Mohammad Chand Jamali, Mohammed Abdalhamied M. Abushohada, Anam Tariq, Fahad Saqib Lodhi, Dilbar Urazbaeva, Srikumar Chakravarthi, Joti Devi, Tahlil Nafi, MD. Faisal Ahmed, T. Ramesh, Nikolaos Syrmos, Mustafa Mudhafar. Respiratory Infections by Human Metapneumovirus Epidemiological Evidence and Treatment Prospects. Research Journal of Pharmacy and Technology. 2026;19(8):3905-2. doi: 10.52711/0974-360X.2026.00549 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-8-66
REFERENCE:
1. Davis CR, Stockmann C, Pavia AT, Byington CL, Blaschke AJ, Hersh AL, et al. Incidence, morbidity and costs of humanmetapneumovirus infection in hospitalized children. J Pediatric Infect Dis Soc. 2016; 5(3): 303–311. doi: 10.1093/jpids/piv027.
2. Kumar P, Srivastava M. Prophylactic and therapeutic approaches for human metapneumovirus. Virusdisease. 2018 Dec; 29(4): 434-444. doi: 10.1007/s13337-018-0498-5. Epub 2018 Oct 20. PMID: 30539045; PMCID: PMC6261883.
3. Centers for Disease Control and Prevention (CDC). About human metapneumovirus]. Atlanta (GA): CDC. Available from: https://www.cdc.gov/human-metapneumovirus/about/index.html
4. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5; 360(6): 588-98. doi:10.1056/NEJMoa0804877.
5. Haynes AK, Fowlkes AL, Schneider E, Mutuc JD, Armstrong GL, Gerber SI. Human metapneumovirus circulation in the United States, 2008 to 2014. Pediatrics. 2016 May; 137(5): e20152927. doi:10.1542/peds.2015-2927.
6. Ahmed Mahedi MR, Rawat A, Rabbi F, Babu KS, Tasayco ES, Ore Areche F, et al. Understanding the global transmission and demographic distribution of nipah virus (NiV). Res J Pharm Technol. 2023; 3588–94. Available from: http://dx.doi.org/10.52711/0974-360x.2023.00592
7. Dey D, Ema TI, Biswas P, Aktar S, Islam S, Rinik UR, et al. Antiviral effects of bacteriocin against animal-to-human transmittable mutated SARS-cov-2: A systematic review. Front Agric Sci Eng. 2021; 8(4): 603. Available from: http://dx.doi.org/10.15302/j-fase-2021397
8. Renner M, Paesen GC, Grison CM, Granier S, Grimes JM, Leyrat C. Structural dissection of human metapneumovirus phosphoprotein using small angle X-ray scattering. Sci Rep. 2017; 7: 14865. doi:10.1038/s41598-017-14448-z
9. Van Den Bergh A, Bailly B, Guillon P, von Itzstein M, Dirr L. Novel insights into the host cell glycan binding profile of human metapneumovirus. J Virol. 2024; 98: e0164123. doi:10.1128/jvi.01641-23.
10. Velayutham TS, Ivanciuc T, Garofalo RP, Casola A. Role of human metapneumovirus glycoprotein G in modulation of immune responses. Front Immunol. 2022; 13: 962925. doi:10.3389/fimmu.2022.962925.
11. Pan J, Peng R, Geng H, Chen R, Li M, Li Z, et al. Structure of the human metapneumovirus polymerase phosphoprotein complex. Nature. 2020; 577(7790): 275-279. doi:10.1038/s41586-019-1759-1.
12. Cao D, Gao Y, Liang B. Structural insights into the respiratory syncytial virus RNA synthesis complexes. Viruses. 2021; 13(5): 834. doi:10.3390/v13050834.
13. Masante C, Najjar FE, Chang A, Jones A, Moncman CL, Dutch RE. The human metapneumovirus small hydrophobic protein has properties consistent with those of a viroporin and can modulate viral fusogenic activity. J Virol. 2014; 88: 6423–6433. doi: 10.1128/JVI.02848-13
14. Hastings AK, Amato KR, Wen SC, Peterson LS, Williams JV. Human metapneumovirus small hydrophobic (SH) protein downregulates type I IFN pathway signaling by affecting STAT1 expression and phosphorylation. Virology. 2016; 494: 248–256. doi: 10.1016/j.virol.2016.04.022.
15. Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020; 383(5): 415-425. doi:10.1056/NEJMoa1913556.
16. Jones JM, Mbaeyi S, Wallace M, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep. 2023; 72(34): 920-925. doi:10.15585/mmwr.mm7234a4
17. Wen X, et al. Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode. Cell Host Microbe. 2023; 31(9): 1288-1300.e6. doi:10.1016/j.chom.2023.07.002.
18. Caban M, et al. Cross-protective antibodies against common endemic respiratory viruses. Nat Commun. 2023; 14: 798. doi:10.1038/s41467-023-36459-3.
19. Fausther-Bovendo H, et al. A candidate therapeutic monoclonal antibody inhibits both HRSV and HMPV replication in mice. Biomedicines. 2022; 10(10): 2516. doi:10.3390/biomedicines10102516
20. Kampmann B, Munoz FM, Beigi RH, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023; 388(16): 1451–1464. doi:10.1056/NEJMoa2216480
21. Miller RJ, Mousa JJ. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization. Curr Opin Virol. 2023; 61: 101337. doi:10.1016/j.coviro.2023.101337.
22. Trinite B, et al. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice. Vaccine. 2024; 42: 3474–85. doi:10.1016/j.vaccine.2024.04.048.
23. Huang J, Miller RJ, Mousa JJ. A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein. Front Immunol. 2022; 13: 941865. doi:10.3389/fimmu.2022.941865.
24. Nikiforow S, et al. ALVR106, an off-the-shelf, multivirus-specific T-cell therapy, for the treatment of respiratory viral infections: Results from a Phase 1, First-in-human, dose-ranging trial. Transplant Cell Ther. 2024; 30(Suppl): S83–S84. doi:10.1016/j.jtct.2023.12.135.
25. Ahmed MDF. Learning from COVID-19: Building better preparedness for human metapneumovirus outbreaks. Medicine India [Internet]. 2025 [cited 2025 Jun 5]; 0(1): 1–2. http://dx.doi.org/10.25259/medindia_3_2025
26. Islam SMS, Laskar N, Reza M, Ahmed MF, Iqbal H, De Guia LC, Syrmos N. Human Metapneumovirus: A critical review of its impact on the immune system and clinical implications. J Curr Health Sci. 2025; 5(2): 77–90. doi:10.47679/jchs.2025111
27. Kruger N, Laufer SA, Pillaiyar T. An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities. Drug Discov Today [Internet]. 2025; 30(5): 104364. Available from: http://dx.doi.org/10.1016/j.drudis.2025.104364
28. Adams O, Weis J, Jasinska K, Vogel M, Tenenbaum T. Comparison of human metapneumovirus, respiratory syncytial virus and Rhinovirus respiratory tract infections in young children admitted to hospital. J Med Virol. 2015; 87(2): 275–280. doi: 10.1002/jmv.24025.
29. Esposito S, Mastrolia MV. Metapneumovirus Infections and Respiratory Complications. Semin Respir Crit Care Med. 2016 Aug; 37(4): 512-21. doi: 10.1055/s-0036-1584800. Epub 2016 Aug 3. PMID: 27486733; PMCID: PMC7171707.
30. Kumar P, Srivastava M. Prophylactic and therapeutic approaches for human metapneumovirus. Virusdisease. 2018 Dec; 29(4): 434-444. doi: 10.1007/s13337-018-0498-5. Epub 2018 Oct 20. PMID: 30539045; PMCID: PMC6261883.
31. Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017; 8: 167–181. doi: 10.1038/s41467-017-00170-x.
32. Márquez-Escobar VA, Tirado-Mendoza R, Noyola DE, Gutiérrez-Ortega A, Alpuche-Solís AG. HRA2pl peptide: a fusion inhibitor for human metapneumovirus produced in tobacco plants by transient transformation. Planta. 2015 doi: 10.1007/s00425-015-2277-5.
33. Schuster JE, Cox RG, Hastings AK, Boyd KL, Wadia J, Chen Z, et al. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus. J Infect Dis. 2015; 211: 216–225. doi: 10.1093/infdis/jiu307.
34. Sanders B, Koldijk M, Schuitemaker H, et al. Inactivated viral vaccines, chapter 2. In: Nunnally BK, et al., editors. Vaccine analysis: strategies, principles, and control. Dordrecht: Springer; 2015. 45–80.
35. Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, et al. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in non-human primates. Vaccines. 2016; 34(7): 950–956. doi: 10.1016/j.vaccine.2015.12.045.
36. Russell CJ, Jones BG, Sealy RE, Surman SL, Mason JL, Hayden RT, et al. A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge. Virology. 2017; 509: 60–66. doi: 10.1016/j.virol.2017.05.021.
37. Aerts L, Rheaume C, Carbonneau J, Lavigne S, Couture C, Hamelin ME, et al. Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines. J Gen Virol. 2015; 96: 767–774. doi: 10.1099/vir.0.000031.
38. Battles MB, Mas V, Olmedillas E, Lano O, Vazquez M, Rodriguez L, et al. Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein. Nat Commun. 2017; 8: 1528. doi: 10.1038/s41467-017-01708-9.
39. Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015; 479: 379–392. doi: 10.1016/j.virol.2015.03.032.
40. Zhou B, Meliopoulos VA, Wang W, Lin X, Stucker KM, Halpin RA, et al. Reversion of cold-adapted live attenuated influenza vaccine into a pathogenic virus. J Virol. 2016; 90: 8454–8463. doi: 10.1128/JVI.00163-16.
41. Cai H, Zhang Y, Ma Y, Sun J, Liang X, Li J. Zinc binding activity of human metapneumovirus M-2 protein is indispensable for viral replication and pathogenesis in vivo. J Virol. 2015; 89(12): 6391–6405. doi: 10.1128/JVI.03488-14.
42. Ren J, Phan T, Bao X. Recent vaccine development for human metapneumovirus. J Gen Virol. 2015; 96: 1515–1520. doi: 10.1099/vir.0.000083.